Portfolio of Oral Selective α4β7 Inhibitors Acquired from EA Pharma, Eisai’s GI Subsidiary Phase 2 Clinical Program in Ulcerative Colitis to Start in First Half of 2025 with Lead Asset Seasoned Executive Team with History of Execution in Inflammatory Bowel Disease Drug Development toJoin Ensho on July 1 Founded by Neena Bitritto-Garg, Veteran Biotech Equity Research Analyst and Former Eisai Staffer MORRIS PLAINS, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Ensho Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases, launched today with the announcement that it has acquired a portfolio of oral α4β7 integrin inhibitors through a worldwide exclusive license agreement with EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd.

从EA Pharma收购的口服选择性α4β7抑制剂组合，Eisai的GI子公司溃疡性结肠炎2期临床计划将于2025年上半年启动，领先的资产经验丰富的执行团队具有炎症性肠病药物开发的执行历史，于7月1日加入恩施州，由经验丰富的生物技术股权研究分析师尼娜·比特里托·加格（Neena Bitritto Garg）成立，前Eisai员工莫里斯·普莱恩斯（MORRIS PLAINS），新泽西州，2024年6月27日（环球新闻网）——恩施州治疗公司（Ensho Therapeutics，Inc.），一家私营的临床阶段生物制药公司，专注于为炎症性疾病患者开发突破性的口服疗法，今天宣布收购了口服α4β7组合整合素抑制剂通过与Eisai有限公司的子公司EA Pharma Co.，Ltd.的全球独家许可协议。

Under the terms of the agreement, Ensho has the right to develop, manufacture, and commercialize these assets globally, excluding certain Asian jurisdictions. The two companies jointly announced the exclusive license agreement in a separate press release today. Based on results of an extensive Phase 1 clinical program, Ensho has selected NSHO-101, (also known as EA1080), as its lead drug candidate from the portfolio.

根据协议条款，恩施州有权在全球范围内开发、制造和商业化这些资产，不包括某些亚洲司法管辖区。这两家公司今天在另一份新闻稿中联合宣布了独家许可协议。根据广泛的第一阶段临床计划的结果，Ensho从投资组合中选择了NSHO-101（也称为EA1080）作为其主要候选药物。

The Phase 1 program evaluated single and multiple ascending doses of NSHO-101 in over 180 healthy subjects. Results demonstrated favorable pharmacokinetics (PK) and pharmacodynamics (PD), including target engagement. NSHO-101 was generally safe and well-tolerated in healthy subjects. Results of the Phase 1 program support Ensho’s plans to initiate Phase 2 clinical development in the first half of 2025, starting with ulcerative colitis (UC).

第一阶段计划评估了180多名健康受试者单次和多次递增剂量的NSHO-101。结果显示有利的药代动力学（PK）和药效学（PD），包括靶标参与。NSHO-101在健康受试者中通常是安全的并且耐受性良好。。

Neena Bitritto-Garg, CFA, founder, president and chief executive officer of Ensho, stated,.

恩施霍州创始人、总裁兼首席执行官、首席财务官尼娜·比特里托·加格表示，。